; (iii) outline the timeline under which the Committee is required to determine, based on such report, whether the manufacturer list price and retail price is reasonable for each applicable drug; and (iv) publish such proposed process, methodology, and timeline on the internet website of the Committee. (B) Public input Not later than 60 days after publication of the proposed process, methodology, and timeline under subparagraph (A), the Committee shall hold a minimum of 2 public stakeholder meetings to solicit feedback on such proposed process, methodology, and timeline. (C) Publication of final process, methodology, and timeline Not later than 30 months after receipt of the report under section 4, the Committee shall publish a final process, methodology, and timeline on the Committee’s internet website. (D) Updates to process, methodology, and timeline The Committee may make changes and updates to the final process, methodology, and timeline as necessary. Any such changes or updates shall be published on the internet website of the Committee. (3) Issuance of reasonable pricing determination (A) Determinations The Committee shall issue a reasonable pricing determination for each applicable drug that— (i) is based on a review of the information submitted under section 6(a)